- Eyecelerator, in collaboration with Unither Pharmaceuticals and ophthalmology CRO Ora, launched an initiative focused on advancing clinical development pathways.
- The collaboration highlights the role of CROs in clinical trial design, execution, and regulatory strategy in ophthalmology.
Eyecelerator has partnered with Unither Pharmaceuticals and ophthalmology-focused contract research organization (CRO) Ora to explore more efficient pathways for advancing eye care innovations from development to commercialization. The collaboration brings together clinical, manufacturing, and regulatory expertise to support ophthalmic drug development.
Ora, as the CRO partner, plays a central role in the initiative by contributing clinical trial design, execution, and regulatory strategy capabilities. The partnership reflects the increasing reliance on specialized CROs in ophthalmology, where therapeutic development requires targeted expertise in study design and patient populations.
The initiative focuses on aligning clinical research with manufacturing and commercialization strategies. By integrating Ora’s CRO capabilities with Unither’s drug delivery and manufacturing expertise, the collaboration aims to streamline development timelines and improve coordination across the product lifecycle.
The partnership also highlights the growing importance of CRO-led clinical development in complex therapeutic areas such as ophthalmology. Sponsors are increasingly leveraging specialized CROs to navigate regulatory requirements, optimize trial design, and improve the likelihood of successful outcomes.
“This collaboration is designed to help innovators navigate the path to market by aligning clinical development, manufacturing, and regulatory expertise to bring new ophthalmic therapies to patients more efficiently.”
Eyecelerator Official announcement
Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing. 
